ArticleStem cell reports2025
Modeling glioma intratumoral heterogeneity with primary human neural stem and progenitor cells.
Article in Stem cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.Molecular therapy. Oncology · 2026Article
- Chiropteran (Animals : an open access journal from MDPI · 2026Article
- Isolation of postnatal human neural stem cells.bioRxiv : the preprint server for biology · 2026Article
- Modeling pediatric brain tumors with human stem cells.Frontiers in cellular neuroscience · 2026Review
- Perturbing neural stem cell fate in glioblastoma heterogeneity and beyond.Stem cell reports · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are notorious for their intratumoral heterogeneity, which drives therapy resistance. Glioma tumor cells mimic a neural stem cell (NSC) hierarchy reminiscent of normal brain development. How intratumoral heterogeneity is shaped by cell-of-origin and various driver mutations is not fully understood. We develop a model of glioma initiation using neural stem and progenitor cells (NSPCs) purified from midgestational human brain tissue, including tripotent NSCs, bipotent glial progenitor cells (GPCs), and unipotent oligodendrocyte progenitor cells (OPCs). We transduced these isogenic lines with defined combinations of oncogenic drivers (TP53, NF1, CDK4, EGFR, and PDGFRA) and transplanted them into mice. We find that OPC-derived tumors harbored a higher proportion of differentiated oligodendrocyte-like cells, reminiscent of low-grade oligodendrogliomas. CDK4 drove a neuron-like subtype, while EGFR drove a GPC-like subtype. Our platform is highly adaptable and allows for modular and systematic interrogation of how cell-of-origin and specific driver mutations shape the tumor landscape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.